Login to Your Account

Kala lands $22.5M to test mucous-piercing nanoparticles

By Michael Fitzhugh
Staff Writer

Wednesday, April 23, 2014
Kala Pharmaceuticals Inc. has completed a $22.5 million financing to fund four trials of the company's mucous-penetrating nanoparticle platform and its lead application in fighting inflammation after cataract surgery.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription